Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

5.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.1K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

2.9K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.9K
Standards of Care II01:19

Standards of Care II

871
Nurses bear specific legal responsibilities under several federal statutes, including:
871
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.6K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

Investigational new drugs·2026
Same author

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma.

Transplantation and cellular therapy·2026
Same author

Tumor-infiltrating lymphocyte therapy in metastatic vulvar melanoma: A case report and review of the literature.

Gynecologic oncology reports·2026
Same author

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cancer discovery·2026
Same author

Atypical Coxsackievirus A6 Vesiculobullous Presentation in an Adult.

International journal of dermatology·2026

Related Experiment Video

Updated: Nov 9, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.

Susan M Swetter1, John A Thompson2, Mark R Albertini3

  • 11Stanford Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN
|April 12, 2021
PubMed
Summary

The National Comprehensive Cancer Network (NCCN) Guidelines for Cutaneous Melanoma have been updated, incorporating new principles for molecular testing, systemic therapy, and brain metastasis management. Key revisions also address pathology and surgical recommendations for melanoma treatment.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.1K

Related Experiment Videos

Last Updated: Nov 9, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.1K

Area of Science:

  • Oncology
  • Dermatology
  • Clinical Guidelines

Background:

  • The NCCN Guidelines for Cutaneous Melanoma undergo regular updates to reflect advancements in diagnosis and treatment.
  • Recent updates have focused on expanding treatment pathways and incorporating new principles for managing melanoma.

Purpose of the Study:

  • To summarize key modifications and additions to the NCCN Guidelines for Cutaneous Melanoma, v1.2021.
  • To highlight changes in pathology, surgical recommendations, and systemic therapy options for advanced melanoma.

Main Methods:

  • Review of the NCCN Guidelines for Melanoma: Cutaneous, focusing on updates from v2.2019 to v1.2021.
  • Analysis of newly added and revised sections, including microscopic satellitosis, molecular testing, systemic therapy, brain metastases, pathology, surgical margins, sentinel lymph node biopsy, lymph node dissection, and radiation therapy.

Main Results:

  • Inclusion of treatment pathways for microscopic satellitosis (v2.2020).
  • New Principles sections on Molecular Testing (v2.2019), Systemic Therapy Considerations (v2.2020), and Brain Metastases Management (v3.2020).
  • Revisions in v1.2021 to Pathology, Surgical Margins, Sentinel Lymph Node Biopsy, Lymph Node Dissection, and Radiation Therapy principles.

Conclusions:

  • The updated NCCN Guidelines offer refined approaches to melanoma diagnosis and treatment.
  • Emphasis on molecular testing and systemic therapy for advanced melanoma patients.
  • Significant revisions in surgical and pathological recommendations aim to improve patient outcomes.